Beactica, the leading Swedish fragment-based drug discovery company, today announced the appointment of Dr Gisela Sitbon to its Board. Dr Sitbon, Deputy Region Director at Innovationsbron AB, brings more than 25 years experience from the life science industry within the areas of business development, R&D management and quality assurance to the Company. Read more…
Beactica AB, the leading Swedish fragment-based drug discovery company, today announced a new investment and the addition of Innovationsbron AB to its shareholders. They join Uppsala University Holding Company and the founders as continuing investors. The funds will be used to finance the progression of Beactica’s internal drug discovery pipeline. Read more…
Beactica, the leading Swedish fragment-based drug discovery company, today announced the appointment of Professor Bo Öberg to its Board. Professor Öberg, CEO of Medivir HIV Franchise AB, brings almost 40 years of pharmaceutical industry experience as a senior executive and board member in both biotechnology and pharmaceutical companies. Read more…
Beactica, the Swedish fragment-based drug discovery company, today announced its participation in a Marie Curie Initial Training Network (ITN). The ITN, called BrainTrain, is funded through the 7th EU Framework Programme and aims to deliver 15 skilled early stage researchers in the field of neuroscience. The network is composed of eight leading EU institutes (Amsterdam, London, Paris, Heidelberg, Stockholm, Magdeburg, Leuven and Trieste) together with Japanese RIKEN and five commercial partners. Read more…
Beactica AB, the Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Cubist Pharmaceuticals, Inc. (Lexington, MA; NASDAQ: CBST). Under the agreement, Beactica will use its Sprint™ surface plasmon resonance (SPR)-integrated drug discovery platform to target multi-component proteins from pathogenic bacteria of interest to Cubist. Financial terms of the agreement were not disclosed. Read more…
Beactica AB, the Swedish fragment-based drug discovery company, today announced a new research collaboration agreement with GE Healthcare (Chalfont St. Giles, UK), the world leading provider of molecular interaction analysis tools, and Uppsala University (Sweden). The collaboration combines Beactica’s unique approach to fragment-based drug discovery and GE Healthcare’s Biacore™ technology with enzymology expertise from Uppsala University. Read more…
Beactica AB, a fragment-based drug discovery company spun out of Uppsala University, today announced a new investment and the addition of Uppsala University Holding Company to its shareholders. The funding will support Beactica’s growing internal drug discovery pipeline. Read more…
Two leading companies in the area of fragment-based drug discovery (FBDD) today announced a new commercial alliance. IOTA Pharmaceuticals Ltd, based in Cambridge, UK, and Beactica AB, based in Uppsala, Sweden, will join forces to deploy a proprietary FBDD-based lead discovery and optimization platform.
Read more…
Beactica AB announced today that it has entered into a drug discovery collaboration agreement with Arrow Therapeutics Ltd (London, UK) whereby Beactica will direct its novel characterisation technology at selected Arrow compounds against a confidential target. Read more…
Beactica, the specialist drug discovery company spun out of Uppsala University in 2006, announced today that it has moved into new premises at the Uppsala Biomedical Centre. Read more…
Beactica, the specialist drug discovery company spun out of Uppsala University in 2006, will partner in two separate projects both of which have been selected for major grants through the 7th EU Framework Programme. In each project Beactica will apply its drug discovery platform to accelerate the identification of novel compounds with high development potential to address significant clinical needs. The total EU contribution for the two projects exceeds € 12.5 million of which Beactica will receive about € 700 000. Read more…
Beactica receives continued funding from Innovationsbron Uppsala to develop its business.
Beactica receives funding from the Swedish Governmental Agency for Innovation Systems (VINNOVA) to establish a European drug discovery project.
Beactica receives funding from ALMI Företagspartner to develop its technology platform.
Beactica wins business competition organised by the Swedish Governmental Agency for Innovation Systems (VINNOVA) and receives funding.
Beactica receives funding from Innovationsbron Uppsala to develop its technology platform.
Beactica receives funding from Uppsala University Holding Company to develop its technology platform.
Beactica is founded in Uppsala by Dr Per Källblad, previously at Medivir AB, and Professor Helena Danielson at Uppsala University.
